Lorlatinib for the treatment of lung cancer

Lorlatinib is an innovative drug used to treat non-small cell lung cancer (NSCLC) with mutations in ALK (tyrosine kinase) and ROS1 (kinase). For lung cancer patients with these genetic mutations, lorlatinib offers a precise and effective treatment.

First, lorlatinib inhibits the activities of ALK and ROS1 kinases through its highly selective targeting. These two gene mutations are key factors in the development of non-small cell lung cancer. The intervention of lorlatinib effectively blocks the transmission of these abnormal signaling pathways, thereby inhibiting the growth and spread of cancer cells.

Secondly, lorlatinib, as a multi-target inhibitor, covers a variety of ALK and ROS1 mutants, including those that are resistant to traditional treatments. This makes lorlatinib an important and effective option for patients who develop resistance during treatment.

In addition, lorlatinib has shown significant efficacy in clinical trials, extending patients' progression survival (Progression-Free Survival, PFS). This means that patients can maintain good disease control for a relatively long period of time while taking lorlatinib, delaying the progression of the disease.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.